KRAS and neoplasm: Indeed, in syngeneic mouse models of oncogenic Kras p.G12D driven pancreatic adenocarcinoma, using LIF neutralizing antibodies, or only gemcitabine, had no effect on tumor growth, while the combined treatment was able to repress tumor growth and improve animal survival [102].